Study design and participant characteristics of a randomized controlled trial of directly administered antiretroviral therapy in opioid treatment programs

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Mullen, Bernadette A ^a,d   Cook, Katie ^a   Moore, Richard D ^a   Rand, Cynthia ^a   Galai, Noya ^b   McCaul, Mary E ^a   Glass, Sheldon ^a   Oursler, Krisann K ^c   Lucas, Gregory M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d Department of Statistics ^*  (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BUPRENORPHINE; INTEGRASE INHIBITOR; METHADONE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICAN AMERICAN; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COCAINE DEPENDENCE; CONTROLLED STUDY; DEMOGRAPHY; DIRECTLY ADMINISTERED ANTIRETROVIRAL THERAPY; DISEASE CLASSIFICATION; FEMALE; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; OPIATE ADDICTION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELF CARE; STUDY DESIGN; TREATMENT DURATION; ADDICTION; BLOOD; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL; DRUG SELF ADMINISTRATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MEDICAL RESEARCH; METHODOLOGY; MIDDLE AGED; TREATMENT OUTCOME; UNITED STATES; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BALTIMORE; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; SELF ADMINISTRATION; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79851513094     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-45     Document Type: Article

References (37)

1. Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel [published erratum appears in JAMA 1998 Jul 8;280(2):134]. JAMA 1998, 279:943-948. 10.1001/jama.279.12.943, 9544769.
2. Ford N, Nachega JB, Engel ME, Mills EJ. Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials. Lancet 2009, 374:2064-2071. 10.1016/S0140-6736(09)61671-8, 19954833.
3. Hart JE, Jeon CY, Ivers LC, Behforouz HL, Caldas A, Drobac PC, et al. Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review. J Acquir Immune Defic Syndr 2010, 54:167-179.
4. Goggin K, Liston RJ, Mitty JA. Modified directly observed therapy for antiretroviral therapy: a primer from the field. Public Health Rep 2007, 122:472-481. 1888521, 17639650.
5. Berg KM, Mouriz J, Li X, Duggan E, Goldberg U, Arnsten JH. Rationale, design, and sample characteristics of a randomized controlled trial of directly observed antiretroviral therapy delivered in methadone clinics. Contemp Clin Trials 2009, 30:481-489. 10.1016/j.cct.2009.05.003, 2728150, 19505589.
6. Berg KM, Litwin A, Li X, Heo M, Arnsten JH. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: A randomized controlled trial. Drug Alcohol Depend 2010,
7. Lucas GM, Mullen BA, Weidle PJ, Hader S, McCaul ME, Moore RD. Directly Administered Antiretroviral Therapy in Methadone Clinics Is Associated with Improved HIV Treatment Outcomes, Compared with Outcomes among Concurrent Comparison Groups. Clin Infect Dis 2006, 42:1628-1635. 10.1086/503905, 16652321.
8. Panel on Clinical Practices for the Treatment of HIV Infection: Department of Health and Human Services Guidelines for the Use of Antiretroviral Therapy in HIV-1-Infected Adults and Adolescents: March 23, 2004. [last accessed January 2011], Panel on Clinical Practices for the Treatment of HIV Infection: Department of Health and Human Services., http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL03232004003.pdf
9. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009, 17:138-145.
10. Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). Am J Prev Med 1994, 10:77-84.
11. Derogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol Med 1983, 13:595-605. 10.1017/S0033291700048017, 6622612.
12. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001, 27:251-259.
13. Saunders JB, Aasland OG, Babor TF, de L, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction 1993, 88:791-804. 10.1111/j.1360-0443.1993.tb02093.x, 8329970.
14. Conway B, Prasad J, Reynolds R, Farley J, Jones M, Jutha S, et al. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin Infect Dis 2004, 38(Suppl 5):S402-8. S402-S408, 10.1086/421404, 15156430.
15. Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999, 13:957-962. 10.1097/00002030-199905280-00012, 10371177.
16. Gourevitch MN, Friedland GH. Interactions between methadone and medications used to treat HIV infection: A review [In Process Citation]. Mt Sinai J Med 2000, 67:429-436.
17. Centers for Disease Control and Prevention 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. MMWR 1992, 41(RR-17):1-19. Centers for Disease Control and Prevention.
18. Lucas GM, Mullen BA, McCaul ME, Weidle PJ, Hader S, Moore RD. Adherence, drug use, and treatment failure in a methadone-clinic-based program of directly administered antiretroviral therapy. AIDS Patient Care STDS 2007, 21:564-574. 10.1089/apc.2006.0192, 17711381.
19. Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, Howard AA, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 2002, 17:377-381. 1495042, 12047736.
20. Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol 2006, 163:412-420. 10.1093/aje/kwj059, 16394200.
21. Wohl AR, Garland WH, Valencia R, Squires K, Witt MD, Kovacs A, et al. A Randomized Trial of Directly Administered Antiretroviral Therapy and Adherence Case Management Intervention. Clin Infect Dis 2006, 42:1619-1627. 10.1086/503906, 16652320.
22. Macalino GE, Hogan JW, Mitty JA, Bazerman LB, Delong AK, Loewenthal H, et al. A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users. AIDS 2007, 21:1473-1477. 10.1097/QAD.0b013e32811ebf68, 17589194.
23. Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis 2007, 45:770-778. 10.1086/521166, 2693907, 17712763.
24. Gross R, Tierney C, Andrade A, Lalama C, Rosenkranz S, Eshleman SH, et al. Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial. Arch Intern Med 2009, 169:1224-1232. 10.1001/archinternmed.2009.172, 2771688, 19597072.
25. Nachega JB, Chaisson RE, Goliath R, Efron A, Chaudhary MA, Ram M, et al. Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. AIDS 2010, 24:1273-1280.
26. Pearson CR, Micek MA, Simoni JM, Hoff PD, Matediana E, Martin DP, et al. Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. J Acquir Immune Defic Syndr 2007, 46:238-244. 10.1097/QAI.0b013e318153f7ba, 17693890.
27. Sarna A, Luchters S, Geibel S, Chersich MF, Munyao P, Kaai S, et al. Short- and Long-Term Efficacy of Modified Directly Observed Antiretroviral Treatment in Mombasa, Kenya: A Randomized Trial. J Acquir Immune Defic Syndr 2008,
28. Taiwo BO, Idoko JA, Welty LJ, Otoh I, Job G, Iyaji PG, et al. Assessing the Viorologic and Adherence Benefits of Patient-Selected HIV Treatment Partners in a Resource-limited Setting. J Acquir Immune Defic Syndr 2010, 54:85-92. 10.1097/01.qai.0000371678.25873.1c, 20418724.
29. Flanigan TP, Mitty JA. The Good, the Bad, and the Ugly: Providing Highly Active Antiretroviral Therapy When It Is Most Difficult. Clin Infect Dis 2006, 42:1636-1638. 10.1086/503916, 16652322.
30. Bangsberg DR, Mundy LM, Tulsky JP. Expanding directly observed therapy: tuberculosis to human immunodeficiency virus. Am J Med 2001, 110:664-666. 10.1016/S0002-9343(01)00729-X, 11382379.
31. Goldie SJ, Paltiel AD, Weinstein MC, Losina E, Seage GR, Kimmel AD, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med 2003, 115:632-641. 10.1016/j.amjmed.2003.07.007, 14656616.
32. Maru DS, Bruce RD, Walton M, Springer SA, Altice FL. Persistence of virological benefits following directly administered antiretroviral therapy among drug users: results from a randomized controlled trial. J Acquir Immune Defic Syndr 2009, 50:176-181. 10.1097/QAI.0b013e3181938e7e, 2670996, 19131891.
33. Taiwo BO, Idoko JA, Marcelin AG, Otoh I, Reddy S, Iyaji PG, et al. Patient-selected treatment partners did not protect against drug resistance during first-line NNRTI-based HAART in a randomized trial. J Acquir Immune Defic Syndr 2010, 54:563-565. 10.1097/QAI.0b013e3181e5112f, 20647829.
34. Brust JC, Litwin AH, Berg KM, Li X, Heo M, Arnsten JH. Directly Observed Antiretroviral Therapy in Substance Abusers Receiving Methadone Maintenance Therapy Does Not Cause Increased Drug Resistance. AIDS Res Hum Retroviruses 2010,
35. Maru DS, Kozal MJ, Bruce RD, Springer SA, Altice FL. Directly administered antiretroviral therapy for HIV-infected drug users does not have an impact on antiretroviral resistance: results from a randomized controlled trial. J Acquir Immune Defic Syndr 2007, 46:555-563. 10.1097/QAI.0b013e318158c0bd, 2684061, 18193497.
36. Wohl DA, Stephenson BL, Golin CE, Kiziah CN, Rosen D, Ngo B, et al. Adherence to directly observed antiretroviral therapy among human immunodeficiency virus-infected prison inmates. Clin Infect Dis 2003, 36:1572-1576. 10.1086/375076, 12802758.
37. Celentano DD, Galai N, Sethi AK, Shah NG, Strathdee SA, Vlahov D, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001, 15:1707-1715. 10.1097/00002030-200109070-00015, 11546947.